Browse studies
Find your next paid study
16 recruiting studies matching your filters
Phase 1
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pha…
Advanced or Metastatic Solid TumorsBreast CancerOvarian Cancer+10 more
Estimated
~$10 – $8,750
858 Therapeutics, Inc.NCT06395519
Phase 1
An Open-Label Phase 1 Dose-Escalation and Expansion Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of PRTH-101 Alone or in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
The goal of this Open-Label Study is to evaluate the safety and tolerability of PRTH-101 alone or in combination with pembrolizumab in adults with advance or m…
Advanced or Metastatic Solid TumorsNon Small Cell Lung CancerNSCLC
Estimated
~$10 – $8,750
Incendia TherapeuticsNCT05753722
Phase 1
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ANS014004 as a Single Agent in Participants With Locally Advanced or Metastatic Solid Tumors
This is a Phase 1, first-in-human, open-label, multi-center study with the aim of exploring the safety, tolerability, PK, and preliminary anti-tumor activity o…
Locally Advanced or Metastatic Solid Tumors
Estimated
~$10 – $8,750
Avistone Biotechnology Co., Ltd.NCT06307795
Phase 1
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ANS03 as a Single Agent in Participants With Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration
This is a first-in-human Phase I, multi-center, open-label study of ANS03 in patients with advanced solid tumors. The study evaluates the safety, tolerability,…
Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration
Estimated
~$10 – $8,750
Avistone Biotechnology Co., Ltd.NCT06716138